CSIMarket
 
Arvinas Inc   (ARVN)
Other Ticker:  
 
 
Price: $42.6000 $-2.25 -5.017%
Day's High: $45.03 Week Perf: -6.33 %
Day's Low: $ 42.40 30 Day Perf: -17.97 %
Volume (M): 864 52 Wk High: $ 53.08
Volume (M$): $ 36,819 52 Wk Avg: $28.75
Open: $44.56 52 Wk Low: $13.57



 Market Capitalization (Millions $) 2,364
 Shares Outstanding (Millions) 55
 Employees 133
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -367
 Cash Flow (TTM) (Millions $) 230
 Capital Exp. (TTM) (Millions $) 3

Arvinas Inc
Arvinas Inc. is a biotechnology company that is based in New Haven, Connecticut. The company specializes in the development of a unique technology called PROTACe or Proteolysis-Targeting Chimera. This involves designing and developing small-molecule drugs that can specifically degrade target proteins within cells. The technology has the potential to revolutionize the way we treat diseases, particularly in areas where there is a high unmet medical need.

Arvinas was founded in 2013 by Dr. Craig Crews, a prominent scientist in the field of protein degradation. The company has since grown to become a leading player in the biotech industry, with over 200 employees and an extensive research and development program.

The company's goal is to develop drugs for diseases that are currently difficult to treat or have no effective treatments available. This includes a focus on oncology, where Arvinas is developing drugs to target specific types of cancer. The company is also working on drugs for neurodegenerative diseases, cardiovascular disease, and certain viral infections.

One of the key advantages of Arvinas' PROTAC technology is its ability to target specific proteins within cells. This allows for a more precise and effective treatment approach, while minimizing side effects. The company is also working on developing drugs that can penetrate the blood-brain barrier, which will be critical in treating neurodegenerative diseases.

Arvinas has a pipeline of drugs in various stages of development. The company's lead drug candidate, ARV-110, is currently in a Phase 2 clinical trial for the treatment of prostate cancer. The company also has several other drugs in preclinical development, including drugs for breast cancer, ovarian cancer, and Alzheimer's disease.

In addition to its internal research and development efforts, Arvinas has established collaborations and partnerships with leading pharmaceutical companies. This includes a collaboration with Pfizer to develop drugs for oncology and a partnership with Genentech to develop PROTAC-based drugs for disease targets.

Overall, Arvinas Inc. is a cutting-edge biotech company with a mission to revolutionize the way we treat diseases. Its unique PROTAC technology has the potential to transform the biotech industry, and the company's extensive research and development efforts have positioned it as a leader in the field. With a strong pipeline of drugs in development and strategic partnerships with leading pharmaceutical companies, Arvinas is well-positioned for future success.


   Company Address: 5 Science Park New Haven 6511 CT
   Company Phone Number: 535-1456   Stock Exchange / Ticker: NASDAQ ARVN
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Arvinas Inc

Arvinas Inc. Sets the Stage for Growth with Strong Fourth Quarter Results

Arvinas Inc., a biotechnology company specializing in targeted protein degradation, recently released its Dec 31, 2023 report, and the results are promising for investors in the stock market. Despite an increase in the shortfall per share compared to the previous year's quarter, there are several positive indicators that demonstrate the company's potential for growth and success.
In the fiscal fourth quarter of 2023, Arvinas Inc. reported a net shortfall of $-154.800 million, a significant improvement from a deficit of $-272.400 million in the same quarter of the previous year. This demonstrates the company's efforts to reduce losses and improve financial performance.

Management Changes

Arvinas Announces Chief Financial Officer Transition and Records Impressive 215.31% Stock Improvement in the Last 3 Months

Published Tue, Feb 20 2024 9:05 PM UTC



Arvinas Inc., a leading biotechnology company specializing in targeted protein degradation, has recently announced the transition of its Chief Financial Officer (CFO), Sean Cassidy, effective February 29, 2024. This significant change in leadership comes at a time when the company has witnessed remarkable growth and success, as evidenced by the impressive 215.31% i...

Management Announcement

Arvinas Bolsters Legal Team, Appoints Jared Freedberg as General Counsel and Grants Inducement Package in Compliance with Nasdaq Listing Rule 5635(c)(4)

Published Tue, Jan 16 2024 10:01 PM UTC


Arvinas Inc., a leading biopharmaceutical company specializing in targeted protein degradation, has taken significant steps to strengthen its legal capabilities with the appointment of Jared Freedberg as General Counsel. In recognition of his expertise and to align with regulatory requirements, the company has also awarded Mr. Freedberg an inducement grant in accordance...

Clinical Study

Arvinas Inc's Vepdegestrant and Palbociclib Combination Show Promising Results in Phase 1b Trial, Revenue Growth Continues

Published Tue, Dec 5 2023 6:34 PM UTC


Arvinas and Pfizer have recently released interim data from a Phase 1b trial of Vepdegestrant, in combination with Palbociclib (IBRANCE), and have announced plans to expand the Vepdegestrant development program. The findings are highly promising, with an overall response rate of 42% and a median progression-free survival of 11.1 months in heavily pre-treated patients. T...

Financing Agreement

Arvinas Secures Oversubscribed $350 Million in Private Placement, Aiming to Advance Targeted Protein Degradation Drug Development

Published Mon, Nov 27 2023 12:01 PM UTC

Arvinas Announces Oversubscribed $350 Million Private Placement
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company focused on developing drugs based on targeted protein degradation, has disclosed an upcoming private placement to raise funds. The company has entered into a securities purchase agreement with a select group of institutional accredited inv...






 

Arvinas Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Arvinas Inc does not provide revenue guidance.

Earnings Outlook
Arvinas Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com